Introduction: In the past decade, the role of B cells in the pathogenesis of multiple sclerosis
(MS) is coming to the forefront. Depletion of B cells by anti-CD20 monoclonal antibodies …

The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …

B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Background Pivotal trials showed good clinical efficiency of the monoclonal antibody
ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS) …

Background Ocrelizumab is a humanized anti-CD20 antibody that has been approved for
the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …

Introduction. Multiple sclerosis (MS) is the most common neurological disease responsible
for early disability in the young working population. In the last two decades, based on …